Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
The campaign seeks to raise awareness about hypertension while emphasising the significance of managing blood pressure for a healthier lifestyle
With India supplying around 60% of the world's vaccine needs and 20-22% of generic exports, the country is dedicated to providing affordable, high-quality drugs and contribute to global accessibility
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
This initiative encapsulates the essence of OPPI’s commitment towards enabling a healthier India
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Subscribe To Our Newsletter & Stay Updated
